Insulin-like growth factors (IGFs) and their specific regulatory binding proteins (IGFBPs) are postulated to play a key role in bone metabolism.
To date, IGFBP-2 through -6 have been characterized in bone cell systems.
In this study we focused on IGFBP-1. 137: 3295-3301, 1996) T HE INSULIN-LIKE growth factors (IGFs) are essential growth factors for bone (l-3). IGF peptides stimulate osteoblastic cell proliferation and protein synthesis in vitro and are expressed by osteoblasts active in matrix formation and remodeling in viva (4-7). The actions of the IGFs are mediated through specific cell membrane receptors and modulated by special IGF-binding proteins (IGFBPs). Osteoblast-derived IGFBP-2 through IGFBP-6 have been suggested to play roles in bone cell physiology and pathophysiology (7) (8) (9) (10) (11) (12) (13) (14) (15) . We propose IGFBP-1 to be a key player as well.
Glucocorticoids regulate IGFBP production and IGF action in various bone cell culture systems (9, 14, 15) . We previously reported differential regulation of IGFBP expression by glucocorticoids in normal adult human osteoblast-like (hOB) cells (9). Glucocorticoid treatment decreased IGFBP-3, -4, and -5 expression, with no effect on IGFBP-6. In contrast, high dose glucocorticoid markedly increased IGFBP-1 messenger RNA (mRNA) expression in hOB cells. This was an unexpected finding because IGFBP-1 expression has been considered highly tissue specific, being limited to liver, kidney, and reproductive tissues in adult humans (16) (17) (18) (19) (20) (21) (Table  I) . On the other hand, dexamethasone treatment increased IGFBP-1 mRNA levels 5-fold. In the presence of insulin, however, the glucocorticoid-induced increase in IGFBP-1 was completely blocked, and no IGFBP-1 mRNA was detectable even with prolonged autoradiographic exposure. IGFBP-3 (2.6 kb), IGFBP-4 (2.2 kb), and IGFBP-5 (6.0 kb) mRNA levels were decreased by 50%, 35%, and 20%, respectively, with dexamethasone treatment of hOB cells as previously reported (9), although the inhibitory effect on IGFBP-5 mRNA was less evident, perhaps due to the different incubation times. The combination of insulin with dexamethasone did not influence these decreases in expression, whereas insulin alone only had a modest effect on IGFBP-3 mRNA (32% increase). Steady state levels of IGFBP-6 (1.3 kb) mRNA were not regulated by insulin or glucocorticoid in hOB cells during this incubation period, and the weak expression of IGFBP-2 mRNA is not shown. Specific glucocorticoid receptor-mediated action was indicated because dexamethasone was more potent than cortisol in stimulating IGFBP-1 expression, whereas p-estradiol and progesterone were without effect in hOB cells (Fig. 2) . Changes in IGFBP-1 gene expression in hOB cells were reflected in translated protein (Table 1) . Dexamethasone treatment for 20 h increased immunoassayable IGFBP-1 levels in the conditioned medium 3-fold. Insulin treatment produced 55% lower levels, and insulin plus dexamethasone resulted in an 80% decrease to nearly undetectable levels of IGFBP-1. In eight experiments, conditioned medium from 40-h dexamethasone-treated hOB cells had 3.1 ? 0.7 rig/ml IGFBP-1, whereas medium from cells treated with dexamethasone in the presence of insulin had 0.8 + 0.2 rig/ml. Low medium IGFBP-1 levels were associated with a significant increase in cell number (0.54 ? 0.02 x lo5 cells for dexamethasone treatment vs. 0.66 t 0.05 X lo5 cells for dexamethasone in the presence of insulin). Immunoblot studies using an IGFBP-l-specific monoclonal antibody confirmed the presence of an -30-kDa band in hog-conditioned medium after dexamethasone treatment (data not shown). To determine the distinctiveness of these findings for normal human osteoblastic cells, normal human fibroblasts as Fig. 1) .
b Nanograms per ml (IGFBP-1 IRMA of 20-h hOB cell-conditioned medium from the experiment in Fig. 1 ). No 3 our conditions. Thus, IGFBP-1 expression and regulation by glucocorticoid appear to be relatively specific for normal human bone cells and are not found in fibroblasts, which are also mesenchymally derived, or in transformed bone cells.
Receptor-mediated suppression of IGFBP-1 expression
As shown in Fig. 3,lO To distinguish between the two receptor types, we used antibodies relatively specific for the human type I IGF receptor (cYIR-3) (35) Blots were stripped and rehybridized with human IGFBP-6 cDNA to establish loading equivalency (see Figs. 1 and 2). (37, 38) . Dexamethasone (100 nM) was present under all conditions. As shown in Table 4 , 1 nM insulin and 1 nM ~W~IGF-I significantly inhibited _dqed;amethasone-IGFBP-1 production by '0, whereas [QAYL-Leu2']IGF-II had no effect. o47-9 completely prevented insulin-induced suppression of IGFBP-1 and reversed Dex + Q-IGF-I 60 t 2.9" 78 2 0.6" 66 2 3.2"
Dex + Q-IGF-II 98 i-2.6 99 t-0.9 100 t-3.6 hOB cells were pretreated for 1 h with a47-9 (1:24 dilution) or oIR-3 (1 r*g/rnl) before the indicated additions.
The 26-h serum-free conditioned media were assayed for IGFBP-1 by IRMA. Dex, Dexamethasone (100 nM The effects of glucocorticoids and insulin on IGFBP-1 expression in hOB cells were unique to this IGFBP; dexamethasone decreased IGFBP-3, -4, and -5 mRNA levels, with no effect on IGFBP-6 levels, and in the presence of dexamethasone, the further addition of insulin had no effect on mRNA levels for any of these IGFBPs. Interestingly, insulin appeared to be a more effective inhibitor of IGFBP-1 expression in the presence of dexamethasone, although the basis for this is unclear. In human hepatocytes, the effects of glucocorticoid and insulin on IGFBP-1 promoter activity are conferred through two proximal glucocorticoid response elements that flank a single insulin response element (17 Given the requirement for significant glucocorticoid stimulation and the potent inhibitory action of insulin, it may be that osteoblast IGFBP-1 production is minimal under normal physiological circumstances. However, in conditions of high integrated glucocorticoid exposure and/or insulin deficiency or resistance, hOB production of IGFBP-1 may be sufficient to influence the actions of IGF on bone. In this respect, it is interesting to postulate a role for osteoblast IGFBP-1 production in the pathogenesis of bone disease associated with prolonged fasting, glucocorticoid excess, and poorly controlled insulin-dependent diabetes mellitus. Indeed, elevated glucocorticoid levels have been identified as a major factor in reduced tibia1 growth and increased plasma IGFBP-1 in streptozotocin-induced diabetic rats, but not in insulin-replete rats (51). In conclusion, our data clearly show that IGFBP-1, produced by osteoblasts and regulated by insulin and glucocorticoids, must be considered as a potential major player in bone metabolism and could have a significant role in the pathogenesis of bone disease.
